109113-39-5

Basic information

• Product Name: 1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine
• Synonyms: 1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine;1-(Phenylsulfonyl)-5-azaindole
• CAS NO: 109113-39-5
• Molecular Formula: C₁₃H₁₀N₂O₂S
• Molecular Weight: 258.2957
• Mol File: 109113-39-5.mol

Chemical Properties

• Melting Point: 124-125 °C
• Boiling Point: 480.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 6.14±0.30(Predicted)
• CAS DataBase Reference: 1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine(109113-39-5)
• EPA Substance Registry System: 1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine(109113-39-5)

Safety Data

• Hazardous Substances Data: 109113-39-5(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine is utilized as a key intermediate in the synthesis of complex organic molecules, particularly in the field of medicinal chemistry. Its unique structure and the presence of the pyrrolopyridine core make it a valuable building block for the development of new pharmaceutical agents.
Used in Drug Discovery:
In the realm of drug discovery, 1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine serves as a potential drug candidate. Its unique structural features and the pyrrolopyridine core, which is prevalent in bioactive molecules, suggest that it may have therapeutic applications. Further research is necessary to explore its potential as a novel therapeutic agent.
Used in Chemical Synthesis Research:
1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine is employed as a subject of study in chemical synthesis research. Its synthesis and reactivity are of interest to scientists working on developing new methods for constructing complex organic molecules, which could have implications for the creation of advanced pharmaceuticals and other chemical products.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, 1-(Phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine is used as a compound with potential therapeutic applications. Its unique structure and the presence of the pyrrolopyridine core indicate that it may be a promising candidate for the development of new drugs, pending further research into its biological and pharmacological properties.

Upstream product

• 1678-53-1 4-nitro-3-methylpyridine 
• 271-34-1 5-azaindole 
• 98-09-9 benzenesulfonyl chloride 
• 148760-46-7 3-(4-Morpholinovinylene)-4-nitropyridine 1-oxide 
• 123367-22-6 (E)-N,N-dimethyl-2-(4-nitro-1-oxidopyridin-3-yl)ethenamine 
• 148760-47-8 3-Dimethylaminovinylene-4-nitropyridine 
• 1074-98-2 3-methyl-4-nitropyridine N-oxide 

Downstream Products

• 877060-44-1 1-benzenesulfonyl-2-iodo-1H-pyrrolo[3,2-c]pyridine 
• 125335-95-7 2-(1-Benzenesulfonyl-1H-pyrrolo<3,2-c>pyridine)-4-(3-diethylaminocarbonyl-2-methoxypyridyl)ketone 
• 148729-73-1 2-(1-Benzenesulfonyl-1H-pyrrolo<3,2-c>pyridine)-4-(3-diethylaminocarbonyl-2-methoxypyridyl)-1,1-ethanol 
• 148729-71-9 2-(1-Benzenesulfonyl-1H-pyrrolo<3,2-c>pyridine)-4-(3-diethylaminocarbonyl-2-methoxypyridyl)methanol 
• 139125-04-5 α-(p-Methoxyphenyl)-α-(1-phenylsulphonyl-1H-pyrrolo<3,2-c>pyridin-2-yl)methanol 
• 109113-41-9 1-benzenesulphonyl-2-acetyl-1H-pyrrolo[3,2-c]pyridine 
• 109113-45-3 1-Benzenesulfonyl-2-hydroxycarbonyl-1H-pyrrolo<3,2-c>pyridine 
• 877060-46-3 1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridine-2-boronic acid 
• 109113-44-2 1-Benzenesulfonyl-2-formyl-1H-pyrrolo<3,2-c>pyridine 
• 1257294-40-8 4-bromo-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine 
• 60290-21-3 4-chloro-1H-pyrrolo-[3,2-c]-pyridine 

Relevant articles and documents

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS

Compounds of formula (I): wherein; R1 is hydrogen or C1-6alkyl;R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy;R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl;R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6 alkyl;A is C—R5 or N;B is C—R6 or N;D is C—R7 or N;with the proviso that at least one of A, B, and D, is N;R5 is hydrogen or C1-6alkyl;R6 is hydrogen or C1-6alkyl;R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy;R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen;R9 is hydrogen or hydroxy;R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

2 - (AZAINDOL- 2 -YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS

Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O-, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C-R5 or N; B is C-R6 or N; D is C-R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

Versatile and convenient methods for the synthesis of C-2 and C-3 functionalised 5-azaindoles

Functionalisation at C-2 and C-3 of N-protected-5-azaindole leads to a variety of very useful new substituted 5-azaindole derivatives in fair to good yields. Georg Thieme Verlag Stuttgart.